TY - JOUR
T1 - Kutane bivirkninger ved behandling med immuncheckpointinhibitorer
AU - Kaae, Jeanette
AU - Carlsen, Berit Christina
AU - Drljevic-Nielsen, Aska
AU - Palshof, Jesper
AU - Svane, Inge Marie
AU - Vestergaard, Christian
N1 - Publisher Copyright:
Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.
PY - 2024/7/15
Y1 - 2024/7/15
N2 - Over the past decade, treatment with immune checkpoint inhibitors (ICI) has been implemented in cancer treatment. It has led to a significant improvement in the prognosis for many types of cancer. ICIs work by inducing the body's immune response against cancer cells. Unfortunately, they can also cause immune-related adverse events in most organ systems, with skin-related adverse events being among the most common. This review provides an overview of existing evidence and clinical experience regarding managing dermatological adverse events associated with ICIs.
AB - Over the past decade, treatment with immune checkpoint inhibitors (ICI) has been implemented in cancer treatment. It has led to a significant improvement in the prognosis for many types of cancer. ICIs work by inducing the body's immune response against cancer cells. Unfortunately, they can also cause immune-related adverse events in most organ systems, with skin-related adverse events being among the most common. This review provides an overview of existing evidence and clinical experience regarding managing dermatological adverse events associated with ICIs.
UR - http://www.scopus.com/inward/record.url?scp=85200939176&partnerID=8YFLogxK
U2 - 10.61409/V03240216
DO - 10.61409/V03240216
M3 - Review
C2 - 39115212
AN - SCOPUS:85200939176
SN - 0041-5782
VL - 186
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
IS - 29
M1 - V03240216
ER -